Under the collaboration, which is exclusive across the parathyroid hormone (PTH) field, Zelos will utilize Aegis’s patented Intravail permeation enhancer technology to develop an intranasal version of ZT-031 for the treatment of osteoporosis and other bone diseases. A subcutaneous formulation of ZT-031 has already successfully completed a 12 month Phase II clinical trial in the treatment of osteoporosis.
Edward Maggio, CEO of Aegis, said: “Aegis looks forward to collaborating with Zelos on the development of intranasal ZT-031. The unique and differentiated product profile and strong clinical results for ZT-031 are impressive, and we believe this PTH analog is an ideal match for our Intravail technology.”